Noise Levels of Neonatal High-Flow Nasal Cannula Devices - An in-vitro Study

Neonatology ◽  
2013 ◽  
Vol 103 (4) ◽  
pp. 264-267 ◽  
Author(s):  
Kai König ◽  
Ellen L. Stock ◽  
Melanie Jarvis
Keyword(s):  
In Vitro Study ◽  
High Flow ◽  
Nasal Cannula ◽  
Vitro Study ◽  
Noise Levels ◽  
High Flow Nasal Cannula

Carbon dioxide washout during high flow nasal cannula versus nasal CPAP support: An in vitro study

2017 ◽  
Vol 52 (6) ◽  
pp. 792-798 ◽  
Author(s):  
Emidio M. Sivieri ◽  
Elizabeth E. Foglia ◽  
Soraya Abbasi
Keyword(s):  
Carbon Dioxide ◽  
In Vitro Study ◽  
High Flow ◽  
Nasal Cannula ◽  
Vitro Study ◽  
High Flow Nasal Cannula ◽  
Nasal Cpap

scholarly journals Optimizing high-flow nasal cannula flow settings in adult hypoxemic patients based on peak inspiratory flow during tidal breathing

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jie Li ◽  
J. Brady Scott ◽  
James B. Fink ◽  
Brooke Reed ◽  
Oriol Roca ◽  
...  
Keyword(s):  
In Vitro Study ◽  
Inspiratory Flow ◽  
High Flow ◽  
Nasal Cannula ◽  
Vitro Study ◽  
Patient Comfort ◽  
High Flow Nasal Cannula ◽  
Optimal Flow ◽  
The Individual

Abstract Background Optimal flow settings during high-flow nasal cannula (HFNC) therapy are unknown. We investigated the optimal flow settings during HFNC therapy based on breathing pattern and tidal inspiratory flows in patients with acute hypoxemic respiratory failure (AHRF). Methods We conducted a prospective clinical study in adult hypoxemic patients treated by HFNC with a fraction of inspired oxygen (FIO2) ≥ 0.4. Patient’s peak tidal inspiratory flow (PTIF) was measured and HFNC flows were set to match individual PTIF and then increased by 10 L/min every 5–10 min up to 60 L/min. FIO2 was titrated to maintain pulse oximetry (SpO2) of 90–97%. SpO2/FIO2, respiratory rate (RR), ROX index [(SpO2/FIO2)/RR], and patient comfort were recorded after 5–10 min on each setting. We also conducted an in vitro study to explore the relationship between the HFNC flows and the tracheal FIO2, peak inspiratory and expiratory pressures. Results Forty-nine patients aged 58.0 (SD 14.1) years were enrolled. At enrollment, HFNC flow was set at 45 (38, 50) L/min, with an FIO2 at 0.62 (0.16) to obtain an SpO2/FIO2 of 160 (40). Mean PTIF was 34 (9) L/min. An increase in HFNC flows up to two times of the individual patient’s PTIF, incrementally improved oxygenation but the ROX index plateaued with HFNC flows of 1.34–1.67 times the individual PTIF. In the in vitro study, when the HFNC flow was set higher than PTIF, tracheal peak inspiratory and expiratory pressures increased as HFNC flow increased but the FIO2 did not change. Conclusion Mean PTIF values in most patients with AHRF were between 30 and 40 L/min. We observed improvement in oxygenation with HFNC flows set above patient PTIF. Thus, a pragmatic approach to set optimal flows in patients with AHRF would be to initiate HFNC flow at 40 L/min and titrate the flow based on improvement in ROX index and patient tolerance. Trial registration: ClinicalTrials.gov (NCT03738345). Registered on November 13th, 2018. https://clinicaltrials.gov/ct2/show/NCT03738345?term=NCT03738345&draw=2&rank=1

In vitro evaluation of aerosol drug delivery with and without high flow nasal cannula in children

2019 ◽  
Vol 54 (12) ◽  
pp. 1968-1973 ◽  
Author(s):  
Mahmood A. Alalwan ◽  
James B. Fink ◽  
Arzu Ari
Keyword(s):  
Drug Delivery ◽  
High Flow ◽  
Nasal Cannula ◽  
High Flow Nasal Cannula ◽  
In Vitro Evaluation

IN VITRO AND IN VIVO EVALUATION OF A NEONATAL HIGH-FLOW NASAL CANNULA SYSTEM.

2007 ◽  
Vol 55 (1) ◽  
pp. S97
Author(s):  
A. L. Lampland ◽  
P. A. Meyers ◽  
C. T. Worwa ◽  
B. J. Plumm ◽  
M. C. Mammel
Keyword(s):  
High Flow ◽  
Nasal Cannula ◽  
High Flow Nasal Cannula ◽  
In Vivo Evaluation

scholarly journals In Vitro Study of the Effect of Breathing Pattern on Aerosol Delivery During High-Flow Nasal Therapy

2019 ◽  
Vol 5 (1) ◽  
pp. 43-54 ◽  
Author(s):  
Gavin Bennett ◽  
Mary Joyce ◽  
Louise Sweeney ◽  
Ronan MacLoughlin
Keyword(s):  
Breathing Pattern ◽  
In Vitro Study ◽  
High Flow ◽  
Vitro Study ◽  
Aerosol Delivery

A comparative in vitro study of standard facemask jet nebulization and high-flow nebulization in bronchiolitis

2019 ◽  
Vol 45 (1-2) ◽  
pp. 13-21 ◽  
Author(s):  
Juan Valencia-Ramos ◽  
Juan Arnaez ◽  
José Manuel Benito ◽  
Alicia Mirás ◽  
Carlos Ochoa ◽  
...  
Keyword(s):  
In Vitro Study ◽  
High Flow ◽  
Vitro Study

scholarly journals Effects of flow rate on transnasal pulmonary aerosol delivery of bronchodilators via high-flow nasal cannula for patients with COPD and asthma: protocol for a randomised controlled trial

BMJ Open ◽  
2019 ◽  
Vol 9 (6) ◽  
pp. e028584
Author(s):  
Jie Li ◽  
Jian Luo ◽  
Yibing Chen ◽  
Lixing Xie ◽  
James B Fink
Keyword(s):  
Randomised Controlled Trial ◽  
Gas Flow ◽  
Controlled Trial ◽  
High Flow ◽  
Nasal Cannula ◽  
Dose Inhaler ◽  
High Flow Nasal Cannula ◽  
Fill Volume ◽  
Randomised Controlled

IntroductionBoth in vitro and in vivo radiolabelled studies on nebulisation via high-flow nasal cannula showed that inhaled dose decreases as the administered gas flow increases. In our previous in vitro study, we investigated the effects of the ratio of gas flow to subject’s peak inspiratory flow (GF:IF) on the aerosol deposition, which increased as the GF:IF decreased, with an optimal GF:IF between 0.1 and 0.5 producing a stable ‘lung’ deposition in both quiet and distressed breathing. Thus, we aim to validate our in vitro findings in subjects with reversible airflow limitations by assessing their response to inhaled bronchodilator.Methods and analysisThis is a single-centre, randomised controlled trial. Subjects with chronic obstructive pulmonary disease or asthma with positive response to 400μg albuterol via metered dose inhaler and valved holding chamber will be enrolled and consented. After a washout period (1–3 days), subjects will be randomly assigned to inhale albuterol with one of three gas flows: 50 L/min, GF:IF=1.0 and GF:IF=0.5. In each arm, subjects will inhale 2 mL saline, followed by escalating doubling doses (0.5, 1, 2 and 4 mg) of albuterol in a fill volume of 2 mL, delivered by a vibrating mesh nebuliser via heated nasal cannula set up at 37°C. An interval of 30 min between each dose of albuterol, with spirometry measured at baseline and after each inhalation. Titration will be terminated if forced expiratory volume in 1 s improvement is <5%, or adverse event is observed.Ethics and disseminationThis trial has been approved by the Ethic Committee of People’s Liberation Army General Hospital, Beijing, China (no. S2018-200-01). The results will be disseminated through peer-reviewed journals, national and international conferences.Trial registration numberNCT03739359; Pre-results.

Sign in / Sign up

Export Citation Format

Share Document